Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/fmc-2023-0013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Updated protein domain annotation of the PARP protein family sheds new light on biological function.
Nucleic Acids Res
August 2023
Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.
Article Synopsis
- AlphaFold2 and other computational tools have advanced structural biology by accurately predicting protein structures, particularly those of the human PARP protein family.
- The study presents a comprehensive analysis of PARP proteins, detailing their structured domains, disordered regions, and functional roles related to protein and nucleic acid modification.
- Key findings include a model for PARP1's dynamics in different states and confirmation of PARP14's capability to bind RNA and perform RNA ADP-ribosylation, although further experimental validation is necessary.
The connection between PARP14 and SARS-CoV-2.
Future Med Chem
February 2023
Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland, 4229, Australia.
Machine Learning for the Identification of a Common Signature for Anti-SSA/Ro 60 Antibody Expression Across Autoimmune Diseases.
Arthritis Rheumatol
October 2022
B Lymphocytes, Autoimmunity and Immunotherapies laboratory, UMR 1227, Université de Brest, INSERM, and University Hospital of Brest, Brest, France.
Objective: Anti-Ro autoantibodies are among the most frequently detected extractable nuclear antigen autoantibodies, mainly associated with primary Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), and undifferentiated connective tissue disease (UCTD). This study was undertaken to determine if there is a common signature for all patients expressing anti-Ro 60 autoantibodies regardless of their disease phenotype.
Methods: Using high-throughput multiomics data collected from the cross-sectional cohort in the PRECISE Systemic Autoimmune Diseases (PRECISESADS) study Innovative Medicines Initiative (IMI) project (genetic, epigenomic, and transcriptomic data, combined with flow cytometry data, multiplexed cytokines, classic serology, and clinical data), we used machine learning to assess the integrated molecular profiling of 520 anti-Ro 60+ patients compared to 511 anti-Ro 60- patients with primary SS, patients with SLE, and patients with UCTD, and 279 healthy controls.
PARPs in lipid metabolism and related diseases.
Prog Lipid Res
November 2021
Department Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Hungary; MTA-DE Lendület Laboratory of Cellular Metabolism, Debrecen, 4032, Hungary; Research Center for Molecular Medicine, Faculty of Medicine, University of Debrecen, 4032, Hungary. Electronic address:
Article Synopsis
- PARPs and tankyrases, initially identified for their role in DNA repair, are now recognized for influencing lipid metabolism through interactions with cholesterol-based compounds and various metabolic processes.
- Several PARP enzymes, including PARP1, PARP2, and tankyrases, are implicated in lipid homeostasis and may disrupt lipid metabolism, contributing to conditions like hyperlipidemia, obesity, and diabetes.
- The review highlights the potential benefits of pharmacological PARP inhibitors in treating these metabolic diseases and suggests repurposing existing inhibitors from cancer treatments.
Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq.
Genes Chromosomes Cancer
August 2015
Department of Pathology, New York Medical College, Westchester Medical Center, Valhalla, NY.
Xp11 (TFE3) translocation renal cell carcinoma (RCC) is officially recognized as a distinct subtype of RCC in the 2004 WHO classification. This neoplasm is characterized by several chromosomal translocations between the TFE3-involving Xp11.2 breakpoint and various fusion partners.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!